Biology subjects

Iwayama, Y.

Publications and source records attributed to Iwayama, Y..

4 recordsLinked to original sources

bioRxiv2025

Elucidation of the mechanism of byproduct DNA synthesis in whole-transcript amplification by poly-A tagging and development of its specific suppression

Poly-A tagging is a whole-transcript amplification method that uses terminal transferase to add poly-A to single-stranded cDNA in a non-template-dependent manner, and is used in highly sensitive single-cell RNA-seq. However, this method has long been reported to amplify byproduct DNA derived from reverse-transcription primers, particularly under conditions of low RNA abundance, leading to experimental complexity and reduced accuracy in quantifying gene expression. In this study, we elucidated the mechanism by which byproduct DNA is amplified at the molecular level and developed a new strategy of suppressing it named Suppression Tagging (SupTag). SupTag makes use of TdT, which has extremely low extension efficiency at the 3' recessive end, to stabilize dA/dT base pairs and inhibit poly-A extension of oligo-dT primers, thereby preventing the formation of precursor DNA for byproduct DNA. We demonstrated that SupTag can specifically suppress byproduct DNA using chemicals such as tetramethylammonium chloride (TMAC), modified nucleotides (e.g., 2F-dATP), and Super T-modified reverse-transcription primers. SupTag improves usability by streamlining purification processes and prevents reductions in sequence read output and quantitative sensitivity caused by byproduct DNA. Additionally, SupTag demonstrated the ability to suppress byproduct DNA amplification without using suppression PCR and is compatible with cDNA amplification introducing different adapter sequences at both ends. This study presents a novel suppression method based on the mechanism of amplification of byproduct DNA in the poly-A tagging method, providing a practical technology enabling high-precision transcriptomic analysis from low-abundance RNA.

molecular biology↗

bioRxiv2020

Role of an atypical cadherin gene, Cdh23 in prepulse inhibition and its implication in schizophrenia

We previously identified quantitative trait loci (QTL) for prepulse inhibition (PPI), an endophenotype of schizophrenia, on mouse chromosome 10 and reported Fabp7 as a candidate gene from an analysis of F2 mice from inbred strains with high (C57BL/6N; B6) and low (C3H/HeN; C3H) PPI levels. Here, we reanalyzed the previously reported QTLs with increased marker density. The highest LOD score (26.66) peaked at a synonymous coding and splice-site variant, c.753G>A (rs257098870), in the Cdh23 gene on chromosome 10; the c.753G (C3H) allele showed a PPI-lowering effect. Bayesian multiple QTL mapping also supported the same variant with a posterior probability of 1. Thus, we engineered the c.753G (C3H) allele into the B6 genetic background, which led to dampened PPI. We also revealed an e-QTL (expression-QTL) effect imparted by the c.753G>A variant for the Cdh23 expression in the brain. In a human study, a homologous variant (c.753G>A; rs769896655) in CDH23 showed a nominally significant enrichment in individuals with schizophrenia. We also identified multiple potentially deleterious CDH23 variants in individuals with schizophrenia. Collectively, the present study reveals a PPI-regulating Cdh23 variant and a possible contribution of CDH23 to schizophrenia susceptibility.

genetics↗

bioRxiv2019

Genetic risks of schizophrenia identified in a matched case-control study

BackgroundGenetic association studies of schizophrenia may be confounded by the pathological heterogeneity and multifactorial nature of this disease. We demonstrated previously that combinations of the three functional single nucleotide polymorphisms (SNPs) rs10770141 of tyrosine hydroxylase (TH) gene, rs4680 of catechol-O-methyltransferase (COMT) gene, and rs1800497 of dopamine D2 receptor (DRD2) gene may be associated with schizophrenia onset, and we tested those associations herein. Methods: We conducted a secondary study of 2,542 individuals in age- and sex-matched case-control populations. The schizophrenia diagnosis was based on the DSM-IV. To reduce the influence of confounders (age and sex), we performed a propensity score matching analysis. Genotyping and associative analyses of rs10770141, rs4680, and rs1800497 with schizophrenia were performed. Results: We analyzed 1,271 schizophrenics (male/female: 574/698; age 47.4{+/-}13.9 years) and 1,271 matched controls (male/female: 603/669; age 46.5{+/-}13.4 years). The estimated odds ratios (ORs) were 1.245 (p<0.001) for rs4680, 1.727 (p<0.0001) for rs1800497, and 1.788 (p<0.0001) for rs10770141. Double SNP analyses revealed the ORs of 2.010 (p<0.0001) for the combination of rs4680*rs1800497, 1.871 (p<0.001) for rs1800497*rs10770141, and 1.428 (p=0.068) for rs4680*rs1800497. Among the individuals with any of the three double SNP risk combinations (which accounted for 35.8% of the involved patients), the estimated OR was 2.224 (p<0.0001). Conclusions: In this validation study, the combinations of functional polymorphisms related to dopaminergic genes were associated with the development of schizophrenia. Analyzing combinations of functional polymorphisms with the control of possible confounders may provide new insights for association research.

genetics↗

bioRxiv2019

Investigation of betaine as a novel psychotherapeutic for schizophrenia

Betaine is known to act against various biological stresses and its levels were reported to be decreased in schizophrenia patients. Using Chdh (a gene for betaine synthesis)-deficient mice and betaine-supplemented inbred mice, we assessed the role of betaine in psychiatric pathophysiology, and its potential as a novel psychotherapeutic, by leveraging metabolomics, behavioral-, transcriptomics and DNA methylation analyses. The Chdh-deficient mice revealed remnants of psychiatric behaviors along with schizophrenia-related molecular perturbations. Betaine supplementation elicited genetic background-dependent improvement in cognitive performance, and suppressed methamphetamine (MAP)-induced behavioral sensitization. Furthermore, betaine rectified the altered antioxidative and proinflammatory responses induced by MAP and in vitro phencyclidine treatments. Notably, betaine levels were decreased in the postmortem brains from schizophrenia, and a coexisting elevated carbonyl stress, a form of oxidative stress, demarcated a subset of schizophrenia with \"betaine deficit-oxidative stress pathology\". We revealed the decrease of betaine levels in glyoxylase 1 (GLO1)-deficient hiPSCs, which shows elevated carbonyl stress, and the efficacy of betaine in alleviating it, thus supporting a causal link between betaine and oxidative stress conditions. Furthermore, a CHDH variant, rs35518479, was identified as a cis-expression quantitative trait locus (QTL) for CHDH expression in postmortem brains from schizophrenia, allowing genotype-based stratification of schizophrenia patients for betaine efficacy. In conclusion, the present study underscores the potential benefit of betaine in a subset of schizophrenia.

neuroscience↗